Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1961 1
1965 1
1968 1
1973 1
1979 1
1980 3
1981 6
1982 9
1983 6
1984 4
1985 4
1986 4
1987 6
1988 2
1989 2
1990 2
1991 3
1992 9
1993 6
1994 2
1995 3
1996 3
1997 3
1999 2
2000 4
2001 2
2002 3
2003 5
2004 7
2005 6
2006 9
2007 11
2008 6
2009 16
2010 14
2011 17
2012 35
2013 31
2014 23
2015 23
2016 24
2017 23
2018 14
2019 21
2020 23
2021 32
2022 39
2023 42
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

476 results

Results by year

Filters applied: . Clear all
Page 1
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.
Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O, Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV, Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen T, Mazutis L, Hollmann TJ, Pe'er D, Rudin CM. Chan JM, et al. Among authors: egger j. Cancer Cell. 2021 Nov 8;39(11):1479-1496.e18. doi: 10.1016/j.ccell.2021.09.008. Epub 2021 Oct 14. Cancer Cell. 2021. PMID: 34653364 Free PMC article.
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
Febres-Aldana CA, Chang JC, Ptashkin R, Wang Y, Gedvilaite E, Baine MK, Travis WD, Ventura K, Bodd F, Yu HA, Quintanal-Villalonga A, Lai WV, Egger JV, Offin M, Ladanyi M, Rudin CM, Rekhtman N. Febres-Aldana CA, et al. Among authors: egger jv. Clin Cancer Res. 2022 Nov 1;28(21):4702-4713. doi: 10.1158/1078-0432.CCR-22-1115. Clin Cancer Res. 2022. PMID: 35792876 Free PMC article.
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM. Chow A, et al. Among authors: egger j. Immunity. 2023 Jan 10;56(1):93-106.e6. doi: 10.1016/j.immuni.2022.12.001. Epub 2022 Dec 26. Immunity. 2023. PMID: 36574773 Free PMC article.
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.
Vanguri RS, Luo J, Aukerman AT, Egger JV, Fong CJ, Horvat N, Pagano A, Araujo-Filho JAB, Geneslaw L, Rizvi H, Sosa R, Boehm KM, Yang SR, Bodd FM, Ventura K, Hollmann TJ, Ginsberg MS, Gao J; MSK MIND Consortium; Hellmann MD, Sauter JL, Shah SP. Vanguri RS, et al. Among authors: egger jv. Nat Cancer. 2022 Oct;3(10):1151-1164. doi: 10.1038/s43018-022-00416-8. Epub 2022 Aug 29. Nat Cancer. 2022. PMID: 36038778 Free PMC article.
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, Beras A, Spencer R, Lopardo J, Bodd F, Montecalvo J, Sauter JL, Chang JC, Buonocore DJ, Travis WD, Sen T, Poirier JT, Rudin CM, Rekhtman N. Baine MK, et al. Among authors: egger jv. J Thorac Oncol. 2020 Dec;15(12):1823-1835. doi: 10.1016/j.jtho.2020.09.009. Epub 2020 Oct 1. J Thorac Oncol. 2020. PMID: 33011388 Free PMC article.
cfDNA methylome profiling for detection and subtyping of small cell lung cancers.
Chemi F, Pearce SP, Clipson A, Hill SM, Conway AM, Richardson SA, Kamieniecka K, Caeser R, White DJ, Mohan S, Foy V, Simpson KL, Galvin M, Frese KK, Priest L, Egger J, Kerr A, Massion PP, Poirier JT, Brady G, Blackhall F, Rothwell DG, Rudin CM, Dive C. Chemi F, et al. Among authors: egger j. Nat Cancer. 2022 Oct;3(10):1260-1270. doi: 10.1038/s43018-022-00415-9. Epub 2022 Aug 8. Nat Cancer. 2022. PMID: 35941262 Free PMC article.
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Rizvi H, Egger J, Plodkowski AJ, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Altan M, Heymach JV, Skoulidis F, Gainor JF, Hellmann MD, Awad MM. Ricciuti B, et al. Among authors: egger j. J Thorac Oncol. 2022 Mar;17(3):399-410. doi: 10.1016/j.jtho.2021.10.013. Epub 2021 Nov 2. J Thorac Oncol. 2022. PMID: 34740862 Free article.
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation.
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, Ray-Kirton J, Tischfield SE, Egger J, Bhanot UK, Linkov I, Asher M, Sinha S, Silber J, Iacobuzio-Donahue CA, Roehrl MH, Hollmann TJ, Yu HA, Qiu J, de Stanchina E, Baine MK, Rekhtman N, Poirier JT, Loomis B, Koche RP, Rudin CM, Sen T. Quintanal-Villalonga A, et al. Among authors: egger j. Cancer Discov. 2021 Dec 1;11(12):3028-3047. doi: 10.1158/2159-8290.CD-20-1863. Cancer Discov. 2021. PMID: 34155000 Free PMC article.
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy.
Quintanal-Villalonga A, Taniguchi H, Hao Y, Chow A, Zhan YA, Chavan SS, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Offin M, Ciampricotti M, Ray-Kirton J, Egger J, Bhanot U, Linkov I, Asher M, Roehrl MH, Qiu J, de Stanchina E, Hollmann TJ, Koche RP, Sen T, Poirier JT, Rudin CM. Quintanal-Villalonga A, et al. Among authors: egger j. Cancer Res. 2022 Feb 1;82(3):472-483. doi: 10.1158/0008-5472.CAN-21-2964. Epub 2021 Nov 23. Cancer Res. 2022. PMID: 34815254 Free PMC article.
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz VR, Lamberti G, Frias RL, Venkatraman D, Fulgenzi CAM, Pecci F, Recondo G, Di Federico A, Barrichello A, Park H, Nishino M, Hambelton GM, Egger JV, Ladanyi M, Digumarthy S, Johnson BE, Christiani DC, Lin X, Gainor JF, Lin JJ, Pinato DJ, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: egger jv. J Thorac Oncol. 2023 Jun;18(6):731-743. doi: 10.1016/j.jtho.2023.01.091. Epub 2023 Feb 10. J Thorac Oncol. 2023. PMID: 36775193 Free PMC article.
476 results